Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 5120

Provisional Schedule

Committee meeting 06 June 2024
Expected publication 14 August 2024

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Stakeholders

Companies sponsors AstraZeneca (osimertinib)
Others Department of Health and Social care
  NHS England
Patient carer groups EGFR Positive UK
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Comparator companies Bristol Myers Squibb (paclitaxel)
  Hospira - CAU not returned, not participating
  Medac - CAU not returned, not participating
  Pierre Fabre - CAU not returned, not participating
  Sandoz - CAU not returned, not participating
  Seacross Pharmaceuticals - CAU not returned, not participating
  Sun Pharmaceuticals - CAU not returned, not participating
  Synchrony Pharma - CAU not returned, not participating
  Teva - CAU not returned, not participating
General commentators All Wales Therapeutic and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare Products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
25 October 2023 Invitation to participate
07 September 2023 - 04 October 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
04 July 2023 In progress. Topic in appraisal.

For further information on our processes and methods, please see our CHTE processes and methods manual